Cargando…

Targeting tachykinin receptors in neuroblastoma

Neuroblastoma is the most common extracranial tumor in children. Despite aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge with survival rates below 50%. Adding targeted drugs to first-line therapy regimens is a promising approach to improve survival in these pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henssen, Anton G., Odersky, Andrea, Szymansky, Annabell, Seiler, Marleen, Althoff, Kristina, Beckers, Anneleen, Speleman, Frank, Schäfers, Simon, De Preter, Katleen, Astrahanseff, Kathy, Struck, Joachim, Schramm, Alexander, Eggert, Angelika, Bergmann, Andreas, Schulte, Johannes H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352132/ https://www.ncbi.nlm.nih.gov/pubmed/27888795 http://dx.doi.org/10.18632/oncotarget.13440

Ejemplares similares

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
por: De Preter, Katleen, et al.
Publicado: (2006)

Correction: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
por: De Preter, Katleen, et al.
Publicado: (2007)

CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23
por: Michels, Evi, et al.
Publicado: (2008)

The mutational landscape of MYCN, Lin28b and ALK(F1174L) driven murine neuroblastoma mimics human disease
por: De Wilde, Bram, et al.
Publicado: (2017)

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies
por: Althoff, K, et al.
Publicado: (2015)

Mutational topography reflects clinical neuroblastoma heterogeneity
por: Rodriguez-Fos, Elias, et al.
Publicado: (2023)

Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells
por: Pajtler, Kristian W., et al.
Publicado: (2014)

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
por: Claeys, Shana, et al.
Publicado: (2017)

Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing
por: Szymansky, Annabell, et al.
Publicado: (2021)

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models
por: Pajtler, Kristian W, et al.
Publicado: (2016)

Meta-mining of copy number profiles of high-risk neuroblastoma tumors
por: Depuydt, Pauline, et al.
Publicado: (2018)

Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
por: Kumps, Candy, et al.
Publicado: (2013)

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2016)

MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2015)

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
por: Decock, Anneleen, et al.
Publicado: (2012)

No evidence for involvement of SDHD in neuroblastoma pathogenesis
por: De Preter, Katleen, et al.
Publicado: (2004)

Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions
por: Schmelz, Karin, et al.
Publicado: (2021)

The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy
por: Van Roy, Nadine, et al.
Publicado: (2009)

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
por: Gottlieb, Aline, et al.
Publicado: (2017)

Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN
por: Fuchs, Steffen, et al.
Publicado: (2023)

Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma
por: Zhai, Lei, et al.
Publicado: (2023)

Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma
por: Kumps, Candy, et al.
Publicado: (2010)

Ovarian steroids regulate tachykinin and tachykinin receptor gene expression in the mouse uterus
por: Pinto, Francisco M, et al.
Publicado: (2009)

MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation
por: De Wyn, Jolien, et al.
Publicado: (2021)

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma
por: Barbieri, Eveline, et al.
Publicado: (2013)

Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma
por: Helmsauer, Konstantin, et al.
Publicado: (2020)

Three tachykinins in mammalian brain
por: Harmar, Anthony J.
Publicado: (1984)

From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma
por: Decaesteker, Bieke, et al.
Publicado: (2021)

Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11
por: De Preter, Katleen, et al.
Publicado: (2005)

N-Cadherin in Neuroblastoma Disease: Expression and Clinical Significance
por: Lammens, Tim, et al.
Publicado: (2012)

Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome
por: Schramm, A, et al.
Publicado: (2012)

Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015)

In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2018)

Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regions
por: De Preter, Katleen, et al.
Publicado: (2008)

Publisher Correction: In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2019)

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
por: Decock, Anneleen, et al.
Publicado: (2015)

DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing
por: Decock, Anneleen, et al.
Publicado: (2016)

Cancer Gene Prioritization for Targeted Resequencing Using FitSNP Scores
por: Fieuw, Annelies, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t327t6801lvbpbl4dm620qb7ic